ライフサイエンスコーパス: nalidixic acid

1 chloramphenicol, but all were susceptible to nalidixic acid.

2 and exhibited intermediate susceptibility to nalidixic acid.

3 ted for strongly by ciprofloxacin but not by nalidixic acid.

4 concentrations of rifampicin, kanamycin, and nalidixic acid.

5 m-sulfamethoxazole; 4 were also resistant to nalidixic acid.

6 pecifically deficient in the SOS response to nalidixic acid.

7 %) demonstrated a MIC > or = 16 microg/mL to nalidixic acid.

8 tment, and which were also hypersensitive to nalidixic acid.

9 om exogenous agents such as UV radiation and nalidixic acid.

10 ve and represent a more specific response to nalidixic acid.

11 e found to be upregulated in the presence of nalidixic acid.

12 lyze indoxyl acetate and their resistance to nalidixic acid.

13 ment of Health were tested for resistance to nalidixic acid.

14 4c was potent as the prototypical quinolone, nalidixic acid (1), with an IC50 value of 58.3 microgram

15 When nalidixic acid, a DNA synthesis inhibitor, was added to

16 on-inducible lexA mutant hypersusceptible to nalidixic acid, a property restricted to fluoroquinolone

17 occus isolates grown on blood agar, colistin-nalidixic acid agar (CNA), and mannitol salt agar (MSA);

18 B streptococcus, with culture using neomycin-nalidixic acid agar (NNA) and LIM broth.

19 eep blood agar, chocolate agar, and colistin-nalidixic acid agar after 24 to 48 h of incubation at 35

20 d sharply increasing trends in resistance to nalidixic acid and ciprofloxacin for both ST and SPA.

21 n it to be more sensitive to CCCP, PMA, PCP, nalidixic acid and DOC than the parent strain.

22 We identified two drugs, nalidixic acid and dorzolamide, that potently inhibit th

23 xacin), and three quinolones (oxolinic acid, nalidixic acid and flumequine) in eggs is presented.

24 e induced in a LexA-dependent manner by both nalidixic acid and mitomycin C, identifying these as mem

25 on and the addition of the gyrase inhibitors nalidixic acid and novobiocin.

26 emiselective blood agar medium incorporating nalidixic acid and sulfamethazine (NAS) is described.

27 ays a role in modulating the SOS response to nalidixic acid and that the response is more complex tha

28 antibiotics (vancomycin, amphotericin B, and nalidixic acid), and the efficacy of solid (Herrold's eg

29 azole, 312 (28%) to tetracycline, 19 (2%) to nalidixic acid, and 6 (0.5%) to ciprofloxacin.

30 In contrast, addition of rifampin, nalidixic acid, and chloramphenicol had little effect on

31 ant resistant to the prototype of quinolone, nalidixic acid, and created complexes on DNA detected by

32 eased spontaneous resistance to rifampin and nalidixic acid, and MMC/uvrD double mutants exhibited hi

33 g tetracycline, chloramphenicol, ampicillin, nalidixic acid, and rifampin.

34 ns known to be required for SOS induction by nalidixic acid are RecA and RecBC.

35 ion elongation was blocked by hydroxyurea or nalidixic acid, arrested cells contained one partially r

36 antially reduced for SOS induction following nalidixic acid but not UV treatment, and which were also

37 ot hydrolyze hippurate, and was sensitive to nalidixic acid but resistant to cephalothin.

38 DNA-damaging agents, such as mitomycin C and nalidixic acid, caused only limited elongation.

39 r alkaline phosphatase, and was resistant to nalidixic acid, cephalothin, and trimethoprim-sulfametho

40 , the MICs and inhibition zone diameters for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxac

41 molar tooth appearance on anaerobic colistin nalidixic acid (CNA) agar which likely facilitated its d

42 iated to determine whether Columbia colistin-nalidixic acid (CNA) agar would be an equally sensitive,

43 nto blood (blood agar plate [BAP]), colistin-nalidixic acid (CNA), and MacConkey agars in 5% CO2 for

44 Disk diffusion using these antibiotics and nalidixic acid failed to detect some low-level-resistant

45 els of the AcrAB-TolC pump, thereby removing nalidixic acid from the organism.

46 sed to rifampicin (transcription inhibitor), nalidixic acid (gyrase inhibitor), or A22 (MreB-cytoskel

47 r characteristics, (ii) the concentration of nalidixic acid, (iii) the 48 organics identified in the

48 A subset of SOS genes lost their response to nalidixic acid in the dnaQ mutant strain, while two test

49 usceptible to ciprofloxacin but resistant to nalidixic acid in vitro, a pattern associated with fluor

50 Overall, these results suggest that nalidixic acid-induced DNA breaks are generated either b

51 repair DNA damage via UV-induced DNA damage, nalidixic acid-induced double-strand breaks, and methyl

52 The prototype quinolone, nalidixic acid, kills wild-type Escherichia coli only by

53 culture on MacConkey agar supplemented with nalidixic acid (MACnal) and compared to overnight broth

54 Resistance to nalidixic acid may be useful in the identification of E.

55 bind not only quinolone antibiotics such as nalidixic acid (NA) and flumequine (FLU), but also salic

56 R), sarafloxacin (SAR), oxolinic acid (OXO), nalidixic acid (NAL) and flumequine (FLU) were separated

57 al distribution of the organism and apparent nalidixic acid (NAL) resistance.

58 ous Fenton-like reactions for the removal of nalidixic acid (NAL), a recalcitrant quinolone antibacte

59 susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typh

60 Typhi [MDRST]); 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST

61 The combination of neomycin-nalidixic acid (NNA) agar and a selective broth medium (

62 on blood agar medium containing neomycin and nalidixic acid (NNA).

63 were 2.2 [ampicillin (AMP), p=0.017] to 23 [nalidixic acid (NX), p<0.001] times more likely to harbo

64 cs, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

65 howed increased survival on media containing nalidixic acid or rifampicin, but did not have an increa

66 ere uncovered as being uninducible by either nalidixic acid or UV treatment.

67 Nalidixic acid passed undegraded through the MBR and was

68 itt broth supplemented with 10 micrograms of nalidixic acid per ml and 15 micrograms of colistin per

69 The cellular response to nalidixic acid perturbation was analyzed using this form

70 were selected on the basis of resistance to nalidixic acid, representing a variety of the most preva

71 s to rifampicin resistance (RifR) (rpoB) and nalidixic acid resistance (NalR) (gyrA).

72 es of spontaneous mutation to rifampicin and nalidixic acid resistance in one medium and one fast str

73 e efflux contributes to the overall level of nalidixic acid resistance.

74 d an identical pattern on PFGE, and all were nalidixic acid resistant.

75 fraction of kanamycin-resistant (Km(r)) and nalidixic acid-resistant (Nal(r)) isolates showed reduce

76 About 10% of the nalidixic acid-resistant (Nal(r)) mutants in a transposi

77 ompared to 100% of those inoculated with the nalidixic acid-resistant (Nal(r)) parent and 100% of tho

78 triaxone was observed, 20 isolates (7%) were nalidixic acid-resistant (NARST).

79 ations in the gyrA gene were present in most nalidixic acid-resistant isolates.

80 758 (38%) were resistant to nalidixic acid (nalidixic acid-resistant S. Typhi [NARST]) and 734 NARST

81 We found a strong association between nalidixic acid-resistant Salmonella enterica serotype En

82 experiments, detection and enumeration of a nalidixic acid-resistant strain of E. coli O157 in bovin

83 Nalidixic acid-resistant strains harbored mutations in G

84 eptibility to various antibiotics, including nalidixic acid, rifampin, novobiocin, and chloramphenico

85 ty of Todd-Hewitt medium with gentamicin and nalidixic acid (SBM) with our current method of direct p

86 e, such as qnr, is often not detected by the nalidixic acid screen test.

87 re resistant to ampicillin, chloramphenicol, nalidixic acid, streptomycin, sulfisoxazole, tetracyclin

88 Quinolone antibacterial drugs such as nalidixic acid target DNA gyrase in Escherichia coli.

89 Nalidixic acid, the prototype antibacterial quinolone, i

90 perturb a GyrA-GyrA dimer interface allowed nalidixic acid to fragment chromosomes and kill cells in

91 A disk diffusion breakpoint was derived for nalidixic acid to serve as a surrogate marker for gyrase

92 Novobiocin and nalidixic acid treatment both resulted in rapid loss of

93 specifically deficient in SOS induction upon nalidixic acid treatment by using a dinD::lacZ reporter

94 of DNA fragments by GyrA antiserum following nalidixic acid treatment of cells.

95 chromosome replication was blocked by either nalidixic acid treatment or thymine starvation, the tran

96 hed greater than 10-fold in the medium after nalidixic acid treatment, suggesting these were released

97 ically necessary for SOS induction following nalidixic acid treatment.

98 bial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) was

99 PANTA reagent (polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin), reconstit

100 several additional SOS genes in response to nalidixic acid using real-time PCR.

101 0 microg of amphotericin B, and 20 microg of nalidixic acid (VAN) per ml.

102 ween high efflux and increased resistance to nalidixic acid was found.

103 The deficient response to nalidixic acid was rescued by the presence of the wild-t

104 rom the production of an antibacterial drug (nalidixic acid) was investigated employing a membrane bi

105 oteins involved in the cytotoxic response to nalidixic acid, we screened for E. coli mutants specific

106 genes not previously known to be induced by nalidixic acid were also reproducibly upregulated.

107 o the selection of the first clinical agent, nalidixic acid, were ever published by the discoverers.

108 he wild, stranded dolphins were sensitive to nalidixic acid, whereas the isolates from the collection